Improvement of RBD-FC Immunogenicity by Using Alum-Sodium Alginate Adjuvant Against SARS-COV-2

被引:1
|
作者
Dehghan, Mahboobeh [1 ]
Askari, Hossein [1 ]
Tohidfar, Masoud [1 ]
Siadat, Seyed Omid Ranaei [2 ]
Fatemi, Fataneh [2 ]
机构
[1] Shahid Beheshti Univ, Fac Life Sci & Biotechnol, Dept Cellular & Mol Biol, Tehran, Iran
[2] Shahid Beheshti Univ, Prot Res Ctr, Tehran, Iran
关键词
aluminum hydroxide; cytokine; immunogenicity; RBD-FC; SARS-CoV-2; sodium alginate; vaccine; RECEPTOR-BINDING DOMAIN; SPIKE PROTEIN; VACCINE ADJUVANTS; DELIVERY-SYSTEMS; CHITOSAN; CORONAVIRUSES; ANTIBODIES;
D O I
10.1111/irv.70018
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BackgroundAdjuvants use several mechanisms to boost immunogenicity and to modulate immune response. The strength of adsorption of antigen by adjuvants can be a determinant factor for significant improvement of immunopotentiation.MethodsWe expressed recombinant RBD-FC in PichiaPink Strain 4 and examined the vaccination of mice by vaccine formulation with different adjuvants (sodium alginate and aluminum hydroxide, alone and together).ResultsSodium alginate significantly increased the immunogenicity and stability of RBD-FC antigen, so RBD-FC formulated with combined alginate and alum (AlSa) and sodium alginate alone showed higher antibody titer and stability. Immunogenicity of RBD-FC:AlSa was determined by serological assays including direct enzyme-linked immunosorbent assay (ELISA) and surrogate virus neutralization test (sVNT). High levels of IgGs and neutralizing antibodies were measured in serum of mice immunized with the RBD-FC:AlSa formulation. On the other hand, cytokines IL-10 and INF-gamma were severely accumulated in response to RBD-FC:AlSa, and after 10 days, their accumulation was significantly declined, whereas IL-4 showed the highest and the lowest accumulation in response to alum and alginate, respectively.ConclusionsOur data may suggest that combination of alum and sodium alginate has a better compatibility with RBD-FC in vaccine formulation.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] α-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants
    Zou, Jintao
    Jing, Haiming
    Zhang, Xiaoli
    Liu, Yiheng
    Zhao, Zhuo
    Duan, Lianli
    Yuan, Yue
    Chen, Zhifu
    Gou, Qiang
    Xiong, Qingshan
    Li, Sisi
    Yang, Feng
    Zeng, Hao
    Zou, Quanming
    Zhang, Jinyong
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [42] Effect of Inactivated Vaccines Against SARS-CoV-2 on Immunogenicity Outcome
    Ma, Yuke
    Du, Yukuan
    Yang, Jingnan
    Wang, Huichao
    Lin, Xuhong
    DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS, 2025, 19
  • [43] Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2
    Almansour, Iman
    Macadato, Nabela Calamata
    Alshammari, Thamer
    PHARMACEUTICALS, 2021, 14 (01) : 1 - 9
  • [44] Deciphering Fc-effector functions against SARS-CoV-2
    Beaudoin-Bussieres, Guillaume
    Finzi, Andres
    TRENDS IN MICROBIOLOGY, 2024, 32 (08) : 756 - 768
  • [45] A type of cryptic epitope-binding antibody on SARS-CoV-2 RBD retains the neutralization against SARS-CoV-2 variants and sarbecoviruses
    Zou, Weiwei
    Zhang, Zeshuai
    Liu, Xinyong
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2025, 298
  • [46] SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1
    Law, John Lok Man
    Logan, Michael
    Joyce, Michael A.
    Landi, Abdolamir
    Hockman, Darren
    Crawford, Kevin
    Johnson, Janelle
    LaChance, Gerald
    Saffran, Holly A.
    Shields, Justin
    Hobart, Eve
    Brassard, Raelynn
    Arutyunova, Elena
    Pabbaraju, Kanti
    Croxen, Matthew
    Tipples, Graham
    Lemieux, M. Joanne
    Tyrrell, D. Lorne
    Houghton, Michael
    VACCINE, 2021, 39 (40) : 5769 - 5779
  • [47] Design and Immunogenicity of SARS-CoV-2 DNA Vaccine Encoding RBD-PVXCP Fusion Protein
    Dormeshkin, Dmitri
    Katsin, Mikalai
    Stegantseva, Maria
    Golenchenko, Sergey
    Shapira, Michail
    Dubovik, Simon
    Lutskovich, Dzmitry
    Kavaleuski, Anton
    Meleshko, Alexander
    VACCINES, 2023, 11 (06)
  • [48] RBD-displaying OMV nanovaccine boosts immunity against SARS-CoV-2
    Feng, Rang
    Xue, Ruo-Yi
    Liu, Chang
    Li, Guo-Cheng
    Deng, Yan
    Jin, Zhe
    Liu, Jing-Yi
    Zhang, Shan-Shan
    Cheng, Hao
    Guo, Man-Ying
    Zou, Quan-Ming
    Li, Hai-Bo
    JOURNAL OF NANOBIOTECHNOLOGY, 2025, 23 (01)
  • [49] Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants
    Haycroft, Ebene R.
    Davis, Samantha K.
    Ramanathan, Pradhipa
    Lopez, Ester
    Purcell, Ruth A.
    Tan, Li Lynn
    Pymm, Phillip
    Wines, Bruce D.
    Hogarth, P. Mark
    Wheatley, Adam K.
    Juno, Jennifer A.
    Redmond, Samuel J.
    Gherardin, Nicholas A.
    Godfrey, Dale I.
    Tham, Wai-Hong
    Selva, Kevin John
    Kent, Stephen J.
    Chung, Amy W.
    MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 2023, 212 (4) : 291 - 305
  • [50] Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants
    Ebene R. Haycroft
    Samantha K. Davis
    Pradhipa Ramanathan
    Ester Lopez
    Ruth A. Purcell
    Li Lynn Tan
    Phillip Pymm
    Bruce D. Wines
    P. Mark Hogarth
    Adam K. Wheatley
    Jennifer A. Juno
    Samuel J. Redmond
    Nicholas A. Gherardin
    Dale I. Godfrey
    Wai-Hong Tham
    Kevin John Selva
    Stephen J. Kent
    Amy W. Chung
    Medical Microbiology and Immunology, 2023, 212 : 291 - 305